Global Parkinson’s Disease Market – Industry Trends and Forecast to 2030

Parkinson’s Disease Market Analysis and Size:

The rise in the prevalence of Parkinson's disease among populations across the globe acts as one of the major factors driving the growth of the Parkinson's disease market. The increase in demand for combination treatments that assist in neural transplantation, prolonged action of unremitting dopaminergic stimulation medicines, and gene therapy and initiatives by government bodies through the form of funding accelerate the Parkinson's disease market growth.

Data Bridge Market Research analyses that the global Parkinson’s disease market which was USD 2.80 billion in 2022, would rocket up to USD 5.66 billion by 2030, and is expected to undergo a CAGR of 9.2 % during the forecast period. Levodopa/Carbidopa segment dominates the drug class segment of the Parkinson’s Disease Market owing to the advancements in technology that have led to the development of advancements in N95 Mask for various use. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Parkinson’s Disease Market Scope and Segmentation

Market Definition

The global Parkinson's disease market refers to the overall market landscape that encompasses the diagnosis, treatment, and management of Parkinson's disease, a progressive neurological disorder that affects movement and coordination.

The market includes various segments related to Parkinson's disease, such as pharmaceuticals, medical devices, therapies, and services. It involves the development, manufacturing, and distribution of drugs, surgical interventions, rehabilitation equipment, and supportive care products and services.

Global Parkinson’s Disease Market Dynamics

Drivers

• Increasing Aging Population:

Parkinson's disease primarily affects older adults, and as the global population continues to age, the prevalence of Parkinson's disease is expected to rise. This demographic shift is a significant driver for the market as it leads to a larger patient pool requiring treatment and management options.

• Technological Advancements:

Advances in technology have had a positive impact on the diagnosis and treatment of Parkinson's disease. Innovative tools such as wearable devices, remote monitoring systems, and improved imaging techniques have enhanced disease management and patient care. These technological advancements drive the growth of the market by providing more effective and personalized treatment options.

• Rising Awareness and Early Diagnosis:

Increasing awareness about Parkinson's disease among healthcare professionals and the general population has led to early detection and diagnosis. Early diagnosis allows for better management of the disease, leading to improved patient outcomes. More individuals are seeking medical help at the early stages, thereby driving the demand for Parkinson's disease therapies and interventions.

Opportunities

• Increasing Research and Development

The pursuit of new and effective treatments for Parkinson's disease remains a priority for pharmaceutical companies, research institutions, and academia. Extensive research and development activities, including the exploration of potential disease-modifying therapies and gene therapies, contribute to the expansion of the market. These efforts bring about advancements in understanding the disease's underlying mechanisms and drive innovation in treatment options.

• Growing Investment in Healthcare:

Governments, private investors, and philanthropic organizations are increasingly recognizing the significance of Parkinson's disease as a global health concern. Consequently, there has been a rise in funding for Parkinson's disease research, drug development, and initiatives aimed at improving patient care. This increased investment boosts the development of new therapies and supports the overall growth of the market.

Restraints/ Challenges

• Lack of understanding of disease mechanisms:

Parkinson's disease is a complex neurodegenerative disorder, and there is still much to learn about its underlying causes and disease progression. The exact mechanisms involved in the development and progression of Parkinson’s are not fully understood, which poses challenges for researchers and drug developers in finding targeted therapies.

• Limited diagnostic tools:

There is a lack of definitive diagnostic tests for Parkinson’s disease, particularly in the early stages. Currently, diagnosis relies on clinical observation of symptoms, which can lead to misdiagnosis or delayed diagnosis. Improved and more accurate diagnostic tools would enable early intervention and better disease management.

This global Parkinson’s disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global Parkinson’s disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In June 2023, Merck known as MSD outside of the United States and Canada, announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market.
• In May 2023, Sandoz, a global leader in off-patent (generic and biosimilar) medicines, announced a multi-year partnership with Just - Evotec Biologics, the Seattle-based subsidiary of Evotec SE.

Global Parkinson’s Disease Market Scope

The global Parkinson’s disease market is segmented on the basis drug class, medical devices, route of administration, distribution channel, and patient care setting. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Levodopa/Carbidopa
• Dopamine Receptor Agonists
• MAO-Inhibitors
• COMT-Inhibitors
• Anticholinergics
• Other Drugs

Medical devices

• Deep Brain Stimulation (DBS) Devices
• Carbidopa/Levodopa Enteral Suspension (Duopa) Delivery Devices

Route of administration

• Oral, Transdermal
• Subcutaneous
• Intestinal Infusion
• Others

Distribution channel

• Hospital Pharmacies
• Clinics
• Retail Pharmacies
• Online Pharmacies

Patient care setting

• Hospitals
• Clinics

Global Parkinson’s Disease Market regional analysis/insights

The global Parkinson’s disease market is analysed and market size insights and trends are provided drug class, medical devices, route of administration, distribution channel, and patient care setting referenced above.

The countries covered in the global Parkinson’s disease market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia- Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, and rest of Middle East and Africa.

North America is expected to dominate the Parkinson’s disease market due to the presence of major key players, high disposable income, high healthcare expenditure, and well-developed healthcare sector in this region.

Asia-Pacific is expected to grow during the forecast period of 2023-2030 due to the increasing research and development activities, rising investment in the healthcare sector, and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The global Parkinson’s disease market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global Parkinson’s disease market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global Parkinson’s disease market. The data is available for historic period 2010-2020.

Competitive Landscape and Global Parkinson’s Disease Market Share Analysis

The global Parkinson’s disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the global Parkinson’s disease market are:

• GlaxoSmithKline plc (U.S.)
• Teva Pharmaceutical Industries Ltd. (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• Impax Laboratories LLC
• AbbVie Inc. (U.S.)
• Bausch Health (U.S.)
• Lundbeck (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• ACADIA Pharmaceuticals Inc. (U.S.)
• Merck & Co. Inc. (U.S.)
• Novartis AG (U.S.)
• UCB S.A. (U.S.)
• Dr. Reddy’s Laboratories Ltd. (India)
• WOCKHARDT (U.S.)
• F. Hoffmann-La Roche Ltd (U.S.)
• STADA Arzneimittel AG (India)
• Orion Corporation (U.S.)
• Mylan N.V (U.S.)
• Cipla Inc. (U.S.)
• Par Pharmaceutical (India)
• DAIICHI SANKYO COMPANY LIMITED (Japan)
• Apotex Inc. (U.S.)

SKU-37132